Quality assurance program and early toxicities in the phase III BONBIS randomized trial evaluating the role of a localized radiation boost in ductal carcinoma in situ.

Fiche publication

Date publication

septembre 2021

Journal

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr PEIGNAUX Karine

Tous les auteurs :
Bourgier C, Cowen D, Castan F, Lemanski C, Gourgou S, Rivera S, Labib A, Peignaux K, Blanc-Onfroy ML, Benyoucef A, Mege A, Douadi-Gaci Z, Racadot S, Latorzeff I, Schick U, Jacquot S, Massabeau C, Guilbert P, Geffrelot J, Ellis S, Lecouillard I, Breton-Callu C, Richard-Tallet A, Boulbair F, Cretin J, Belkacémi Y, Bons F, Azria D, Fenoglietto P

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/34571090

Résumé

To describe the quality assurance (QA) program and early toxicities in the phase III randomized trial BONBIS (NCT00907868) on the role of a localized radiation boost in ductal carcinoma in situ (DCIS).